Sirolimus or Everolimus Improves Survival After Liver Transplantation for Hepatocellular Carcinoma: A Systematic Review and Meta‐Analysis

• Published in: Liver transplantation Vol. 28; no. 6; pp. 1063 - 1077
• Main Authors: Yan, Xiangyu, Huang, Songhan, Yang, Yang, Lu, Ziwen, Li, Feiyu, Jiang, Liyong, Jiang, Yong, Liu, Jun
• Format: Journal Article
• Language: English
• Published: United States Wolters Kluwer Health, Inc 01.06.2022
• Subjects: Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - surgery; Clinical trials; Everolimus - adverse effects; Hepatocellular carcinoma; Humans; Immunosuppression; Immunosuppressive Agents - adverse effects; Inhibitor drugs; Liver cancer; Liver Neoplasms - drug therapy; Liver Neoplasms - surgery; Liver transplantation; Liver Transplantation - adverse effects; Liver transplants; Meta-analysis; Rapamycin; Risk assessment; Sensitivity analysis; Sirolimus - adverse effects; Survival; Systematic review; Targeted cancer therapy; TOR protein; Toxicity

The effects of mammalian target of rapamycin (mTOR) inhibitors (sirolimus [SRL] and everolimus [EVL]) on survival in liver transplantation (LT) recipients with hepatocellular carcinoma (HCC) remain the subject of intense research. Therefore, we performed this systematic review and meta‐analysis to i...